Reversible female contraception: current options and new developments

References

• Daulaire N, Leidl P, Murphy C, Stark L. Promises to keep: the toll of unintended pregnancies on women’s lives in the developing world. Global Health Council, Washington DC, USA (2002).
   Google Scholar
• Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA265(6), 731–736 (1991).
   PubMed Web of Science ®Google Scholar
• Royce RA. Birth spacing – the long and short of it. JAMA295(15), 1837–1838 (2006).
   PubMedGoogle Scholar
• Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA295(15), 1809–1823 (2006).
   PubMed Web of Science ®Google Scholar
• Reynolds HW, Steiner MJ, Cates W Jr. Contraception’s proved potential to fight HIV. Sex. Transm. Infect.81(2), 184–185 (2005).
   PubMedGoogle Scholar
• Davidoff F, Trussell J. Plan B and the politics of doubt. JAMA296(14), 1775–1778 (2006).
   PubMed Web of Science ®Google Scholar
• Shorto R. Contra-contraception. New York Times, NY, USA May 7 (2006).
   Google Scholar
• Bhattacharyya S. Quinacrine sterilization (QS): the ethical issues. Int. J. Gynaecol. Obstet.83(Suppl. 2), S13–S21 (2003).
   Google Scholar
• Steiner MJ, Trussell J, Mehta N, Condon S, Subramaniam S, Bourne D. Communicating contraceptive effectiveness: a randomized controlled trial to inform a World Health Organization family planning handbook. Am. J. Obstet. Gynecol.195(1), 85–91 (2006).
   PubMed Web of Science ®Google Scholar
• Trussell J. The essentials of contraception: efficacy, safety and personal considerations. In: Contraceptive Technology, 18th Edition. Hatcher RA, Trussell J, Stewart F et al. (Eds). Ardent Media Inc., NY, USA 226 (2004).
   Google Scholar
• Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam. Plann. Perspect.28(4), 154–158 (1996).
   PubMedGoogle Scholar
• Product liability and the threat to contraception. Civil Justice Memo No 36. (1999).
   Google Scholar
• Boonstra H, Duran V, Northington Gamble V, Blumenthal P, Dominguez L, Pies C. The “boom and bust phenomenon”: the hopes, dreams, and broken promises of the contraceptive revolution. Contraception61(1), 9–25 (2000).
   PubMed Web of Science ®Google Scholar
• Warner L, Macaluso M, Newman D et al. Condom effectiveness for prevention of C. trachomatis infection. Sex. Transm. Infect.82(3), 265 (2006).
   PubMedGoogle Scholar
• Wald A, Langenberg AG, Krantz E et al. The relationship between condom use and herpes simplex virus acquisition. Ann. Intern. Med.143(10), 707–713 (2005).
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med.354(25), 2645–2654 (2006).
   PubMed Web of Science ®Google Scholar
• Zipper JA, Tatum HJ, Pastene L, Medel M, Rivera M. Metallic copper as an intrauterine contraceptive adjunct to the “T” device. Am. J. Obstet. Gynecol.105(8), 1274–1278 (1969).
   PubMed Web of Science ®Google Scholar
• Alvarez F, Brache V, Fernandez E et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil. Steril.49(5), 768–773 (1988).
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Batar I, Affandi B et al. The ‘frameless’ intrauterine system for long-term, reversible contraception: a review of 15 years of clinical experience. J. Obstet. Gynaecol. Res.29(3), 164–173 (2003).
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J, Coutinho E et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception44(5), 473–480 (1991).
   PubMed Web of Science ®Google Scholar
• Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel-releasing intrauterine system. Br. J. Obstet. Gynaecol.104(3), 285–289 (1997).
   PubMedGoogle Scholar
• Bilian X, Peng-di Z, Shan-chun W. Use of the levonorgestrel-releasing intrauterine system for contraception and treatment of menorrhagia – the Chinese experience. Gynaecol. Forum3, 26–28 (1998).
   Google Scholar
• Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst. Rev. (4), CD002126 (2005).
   Google Scholar
• Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception66(2), 93–99 (2002).
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception71(6), 465–469 (2005).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Luukkainen T. Five years’ experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception72(5), 342–345 (2005).
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr, Diaz S et al. Prolonged effectiveness of Norplant® capsule implants: a 7-year study. Contraception61(3), 187–194 (2000).
   PubMed Web of Science ®Google Scholar
• Funk S, Miller MM, Mishell DR Jr et al. The Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception71(5), 319–326 (2005).
   PubMed Web of Science ®Google Scholar
• Ma G, Song C, Sun H, Yang J, Leng X. A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs. Contraception74(2), 141–147 (2006).
   PubMed Web of Science ®Google Scholar
• Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception74(4), 297–302 (2006).
   PubMedGoogle Scholar
• Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception74(2), 90–99 (2006).
   PubMed Web of Science ®Google Scholar
• DMPA use and skeletal health. ACOG Today49(10), 9 (2005).
   Google Scholar
• World Health Organisation. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception28(1), 1–20 (1983).
   PubMed Web of Science ®Google Scholar
• Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception71(5), 395–398 (2005).
   PubMed Web of Science ®Google Scholar
• Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am. J. Obstet. Gynecol.186(6), 1250–1256 (2002).
   PubMed Web of Science ®Google Scholar
• Maillard-Salin DG, Becourt P, Couarraze G. Physical evaluation of a new patch made of a progestomimetic in a silicone matrix. Int. J. Pharm.199(1), 29–38 (2000).
   PubMed Web of Science ®Google Scholar
• Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception47(1), 97–105 (1993).
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol.95(2), 261–266 (2000).
   PubMed Web of Science ®Google Scholar
• White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception74(4), 293–296 (2006).
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 µg of ethinyl estradiol. Contraception73(3), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum. Reprod. Update12(2), 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• La Guardia E, Ilkins NL, Colagrande F, Humberstone A. Development of transdermal Nestorone spray for contraception. AAPS J.6(4) [poster] (2004) (Abstract W4208).
   Google Scholar
• Young E. Spray-on female contraceptive to start trial. New Sci. 27 November (2003).
   Google Scholar
• Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception73(5), 488–492 (2006).
   PubMed Web of Science ®Google Scholar
• Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet. Gynecol.106(3), 473–482 (2005).
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Brache V et al. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception72(1), 40–45 (2005).
   PubMed Web of Science ®Google Scholar
• Massai R, Quinteros E, Reyes MV et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a Phase II clinical trial. Contraception72(5), 352–357 (2005).
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D, Duijkers I, van Osta G, Dieben T. Maintenance of ovulation inhibition with the 75-µg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception71(1), 8–13 (2005).
   PubMed Web of Science ®Google Scholar
• Collaborative Study Group on the Desogestrel-containing progestogen-only pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 µg/day or levonorgestrel 30 µg/day. Eur. J. Contracept. Reprod. Health Care3(4), 169–178 (1998).
   PubMedGoogle Scholar
• Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. Fam. Plann. Perspect.31(2), 81–87 (1999).
   PubMedGoogle Scholar
• Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database. Syst. Rev. (1), CD003550 (2006).
   Google Scholar
• Joanis C, Latka M, Glover LH, Hamel S. Structural integrity of the female condom after a single use, washing, and disinfection. Contraception62(2), 63–72 (2000).
   PubMed Web of Science ®Google Scholar
• D’Cruz OJ, Uckun FM. Vaginal contraceptive activity of a chelated vanadocene. Contraception72(2), 146–156 (2005).
   PubMed Web of Science ®Google Scholar
• Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA268(4), 477–482 (1992).
   PubMed Web of Science ®Google Scholar
• van Damme L, Ramjee G, Alary M et al. COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet360(9338), 971–977 (2002).
   PubMed Web of Science ®Google Scholar
• Stafford MK, Ward H, Flanagan A et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol.17(4), 327–331 (1998).
   PubMedGoogle Scholar
• Anderson RA, Feathergill KA, Diao XH et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J. Androl.23(3), 426–438 (2002).
   PubMedGoogle Scholar
• Anderson RA, Feathergill K, Diao XH et al. Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception70(5), 415–422 (2004).
   PubMed Web of Science ®Google Scholar
• Scordi-Bello IA, Mosoian A, He C et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother.49(9), 3607–3615 (2005).
   PubMedGoogle Scholar
• Schwartz JL, Mauck C, Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception74(2), 133–140 (2006).
   PubMedGoogle Scholar
• Amaral E, Perdigao A, Souza MH et al. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception73(5), 542–547 (2006).
   PubMed Web of Science ®Google Scholar
• Garg S, Anderson RA, Chany CJ 2nd et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception64(1), 67–75 (2001).
   PubMed Web of Science ®Google Scholar
• Zairi A, Belaid A, Gahbiche A, Hani K. Spermicidal activity of dermaseptins. Contraception72(6), 447–453 (2005).
   PubMed Web of Science ®Google Scholar
• Arevalo M, Jennings V, Nikula M, Sinai I. Efficacy of the new Two Day Method of family planning. Fertil. Steril.82(4), 885–892 (2004).
   PubMed Web of Science ®Google Scholar
• Piaggio G, von Hertzen H, Grimes DA, van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task force on postovulatory methods of fertility regulation. Lancet353(9154), 721 (1999).
   PubMed Web of Science ®Google Scholar
• Glasier A, Baird D. The effects of self-administering emergency contraception. N. Engl. J. Med.339(1), 1–4 (1998).
   PubMed Web of Science ®Google Scholar
• Verpoest WM, Cahill DJ, Harlow CR, Hull MG. Relationship between midcycle luteinizing hormone surge quality and oocyte fertilization. Fertil. Steril.73(1), 75–77 (2000).
   PubMed Web of Science ®Google Scholar
• Davidoff F, Trussell J. Plan B and the politics of doubt. JAMA296(14), 1775–1778 (2006).
   PubMed Web of Science ®Google Scholar
• Durand M, Seppala M, Cravioto Mdel C et al. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception71(6), 451–457 (2005).
   PubMed Web of Science ®Google Scholar
• Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation: a pilot study. Contraception75(2), 112–118 (2007).
   PubMed Web of Science ®Google Scholar
• Trussell J, Ellertson C, Dorflinger L. Effectiveness of the Yuzpe regimen of emergency contraception by cycle day of intercourse: implications for mechanism of action. Contraception67(3), 167–171 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar V, Lal J, Singh MM, Gupta RC. Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Contraception74(2), 165–173 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart F, Trussell J, van Look PFA. Emergency contraception. In: Contraceptive Technology, 18th Edition. Hatcher RA, Trussell J, Stewart F et al. (Eds). Ardent Media, NY, USA 286 (2004).
   Google Scholar
• Griffin PD. The World Health Organization initiative on implantation research. Contraception71(4), 235–238 (2005).
   PubMed Web of Science ®Google Scholar
• Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med. Res. Rev.21(4), 302–347 (2001).
   PubMed Web of Science ®Google Scholar
• Naz RK, Chauhan SC. Human sperm-specific peptide vaccine that causes long-term reversible contraception. Biol. Reprod.67(2), 674–680 (2002).
   PubMedGoogle Scholar
• Dube E, Legare C, Gaudreault C, Sullivan R. Contraceptive responses of female hamsters immunized with recombinant sperm protein P26h. Contraception72(6), 459–467 (2005).
   PubMedGoogle Scholar
• Govind CK, Srivastava N, Gupta SK. Evaluation of the immunocontraceptive potential of Escherichia coli expressed recombinant non-human primate zona pellucida glycoproteins in homologous animal model. Vaccine21(1–2), 78–88 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson RJ, Simms MS, Broome P, Humphreys JE, Bishop MC. A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer. Eur. Urol.45(2), 171–175 (2004).
   PubMed Web of Science ®Google Scholar
• Dhar R, Karmakar S, Sriraman R, Talwar GP, Das C. Efficacy of a recombinant chimeric anti-hCG antibody to prevent human cytotrophoblasts fusion and block progesterone synthesis. Am. J. Reprod. Immunol.51(5), 358–363 (2004).
   PubMedGoogle Scholar
• Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG. Recent advances in contraceptive vaccine development: a mini-review. Hum. Reprod.20(12), 3271–3283 (2005).
   PubMed Web of Science ®Google Scholar
• Center for Disease Control. Ten great public health achievements – United States, 1900–1999. Morb. Mortal. Wkly Rep.48(12), 241–243 (1999).
   PubMedGoogle Scholar
• Doyle LL, Shields WC. Improving contraceptive technology: is it a zero-sum game? Contraception72(5), 321–322 (2005).
   PubMedGoogle Scholar